Skip to main content

Hepion Pharmaceuticals, Inc.

CTRVP
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001583771

In the last 90 days, Hepion Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Other share classesHEPA

Key figures

Insider buysLast 90 days, $825.0K in total
5
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026
0
13F valueReported value at the end of Q2 2026
$0
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding CTRVP, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding CTRVP at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Hepion Pharmaceuticals, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 14, 2026 (view filing)6:30 AM ETSep 311 daysLateLoPriore Vincent SExecutive ChairmanPPurchase+12.5M$0.00$0–22.5M afterDerivative
Aug 12, 2026 (view filing)9:43 PM ETAug 39 daysLateStetz Gary S. IIDirectorPPurchase+500.0K$0.05+$25.0KNew position500.0K after
Aug 12, 2026 (view filing)9:43 PM ETAug 39 daysLateStetz Gary S. IIDirectorPPurchase+500.0K$0.00$0–500.0K afterDerivative
Aug 12, 2026 (view filing)9:41 PM ETAug 39 daysLateStetz Gary S.Interim CEOPPurchase+2.00M$0.05+$100.0K+160.0%3.25M after
Aug 12, 2026 (view filing)9:41 PM ETAug 39 daysLateStetz Gary S.Interim CEOPPurchase+2.00M$0.00$0–2.00M afterDerivative
Aug 12, 2026 (view filing)9:39 PM ETAug 39 daysLatePurcell Michael J.DirectorPPurchase+2.00M$0.05+$100.0K+160.0%3.25M after
Aug 12, 2026 (view filing)9:39 PM ETAug 39 daysLatePurcell Michael J.DirectorPPurchase+2.00M$0.00$0–2.00M afterDerivative
Aug 12, 2026 (view filing)9:36 PM ETAug 39 daysLateAppajosyula SireeshChief Operating OfficerPPurchase+2.00M$0.05+$100.0K+160.0%3.25M after
Aug 12, 2026 (view filing)9:36 PM ETAug 39 daysLateAppajosyula SireeshChief Operating OfficerPPurchase+2.00M$0.00$0–2.00M afterDerivative
Aug 12, 2026 (view filing)9:34 PM ETAug 39 daysLateLoPriore Vincent SExecutive ChairmanPPurchase+10.0M$0.05+$500.0K+160.0%16.3M after2 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in Hepion Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.

View all: Top 10 13F holders, Q2 2026

No institution reported holding CTRVP in 13F filings for Q2 2026.